Government & DoD PercuSense has secured a multi-year contract with U.S. Department of Defense to develop continuous monitoring biosensor technology for detecting exposure to toxic chemicals, indicating strong defense and government sales potential.

Grant-backed Growth Recent grant funding of 2.5 million from the Helmsley Charitable Trust signals credibility and non-dilutive capital that could attract customers seeking proven, well-supported sensing solutions in medical monitoring.

Multi-analyte Appeal The platform's continuous multi-analyte sensing capability positions it for segments needing integrated biosensor data and disease progression insights, aligning with hospital networks, clinics, and research institutions seeking advanced monitoring.

Moderate scale With 11-50 employees and revenue in the 1–10 million range, PercuSense is agile enough for pilot programs and rapid deployments, appealing to mid-market hospitals and government programs seeking innovative medical devices.

Strategic partnerships Existing DoD engagement and government contract history, plus Cloud-based tech stack, suggests opportunities to partner with healthcare agencies, defense contractors, and federal health programs to expand adoption of continuous monitoring biosensors.